Published in Genes Dev on February 15, 2006
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev (2011) 3.04
Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol (2009) 2.89
A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev (2006) 2.78
Specialized roles for cysteine cathepsins in health and disease. J Clin Invest (2010) 2.69
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Pou5f1-dependent EGF expression controls E-cadherin endocytosis, cell adhesion, and zebrafish epiboly movements. Dev Cell (2013) 1.69
Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A (2010) 1.60
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One (2008) 1.55
Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev (2014) 1.46
miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med (2014) 1.45
Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem (2008) 1.43
In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. Proc Natl Acad Sci U S A (2011) 1.42
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer (2012) 1.39
Protease-activated drug development. Theranostics (2012) 1.36
Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res (2009) 1.35
VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res (2009) 1.32
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res (2008) 1.31
Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle (2010) 1.22
Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res (2008) 1.20
Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol (2014) 1.19
Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest (2009) 1.19
Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges. Protoplasma (2014) 1.12
Topical application of activity-based probes for visualization of brain tumor tissue. PLoS One (2012) 1.10
Cathepsins mediate tumor metastasis. World J Biol Chem (2013) 1.07
A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One (2006) 1.07
Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer (2011) 1.04
Cathepsin B: multiple roles in cancer. Proteomics Clin Appl (2014) 1.03
IL-8 and cathepsin B as melanoma serum biomarkers. Int J Mol Sci (2011) 1.00
Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. Neoplasia (2010) 0.98
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Mol Cancer (2014) 0.98
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br J Cancer (2011) 0.97
Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene (2009) 0.97
Genetic deletion of the desmosomal component desmoplakin promotes tumor microinvasion in a mouse model of pancreatic neuroendocrine carcinogenesis. PLoS Genet (2010) 0.96
Soluble E-cadherin: more than a symptom of disease. Front Biosci (Landmark Ed) (2012) 0.95
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. Int J Oncol (2007) 0.94
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol (2008) 0.94
MT-MMPS as Regulators of Vessel Stability Associated with Angiogenesis. Front Pharmacol (2011) 0.94
Cathepsin B trafficking in thyroid carcinoma cells. Thyroid Res (2011) 0.93
Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene (2013) 0.92
Pericellular proteolysis in cancer. Genes Dev (2014) 0.92
Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One (2010) 0.90
Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer (2015) 0.89
Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA. J Oncol (2010) 0.89
Increased expression of cysteine cathepsins in ovarian tissue from chickens with ovarian cancer. Reprod Biol Endocrinol (2010) 0.89
Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol Chem (2010) 0.88
Silencing of atp6v1c1 prevents breast cancer growth and bone metastasis. Int J Biol Sci (2013) 0.87
Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J Biol Chem (2011) 0.87
Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev (2013) 0.87
Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin Exp Metastasis (2013) 0.87
Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target. Front Pharmacol (2012) 0.86
Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradome. Mol Cell Proteomics (2012) 0.86
Multiplex zymography captures stage-specific activity profiles of cathepsins K, L, and S in human breast, lung, and cervical cancer. J Transl Med (2011) 0.86
Direct measurement of cathepsin B activity in the cytosol of apoptotic cells by an activity-based probe. Chem Biol (2009) 0.86
Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res (2011) 0.86
Protective role of cathepsin L in mouse skin carcinogenesis. Mol Carcinog (2011) 0.86
Patient specific proteolytic activity of monocyte-derived macrophages and osteoclasts predicted with temporal kinase activation states during differentiation. Integr Biol (Camb) (2012) 0.86
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Proc Natl Acad Sci U S A (2015) 0.86
Inhibition of cathepsin activity in a cell-based assay by a light-activated ruthenium compound. ChemMedChem (2014) 0.85
Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie (2010) 0.85
Muscadine grape skin extract can antagonize Snail-cathepsin L-mediated invasion, migration and osteoclastogenesis in prostate and breast cancer cells. Carcinogenesis (2015) 0.84
Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins. Biol Chem (2012) 0.84
Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice. PLoS One (2010) 0.83
The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian Cancer. Biomolecules (2015) 0.82
Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis. J Immunol (2012) 0.82
In vivo imaging of mouse tumors by a lipidated cathepsin S substrate. Angew Chem Int Ed Engl (2014) 0.82
Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. Oncotarget (2015) 0.82
Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proc Natl Acad Sci U S A (2010) 0.82
CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner. Oncotarget (2015) 0.81
Cleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis. Tissue Barriers (2013) 0.81
Cytotoxic T lymphocyte antigen-2 alpha induces apoptosis of murine T-lymphoma cells and cardiac fibroblasts and is regulated by cAMP/PKA. Cell Signal (2011) 0.81
Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes Dev (2016) 0.81
Proteinases and their inhibitors in liver cancer. World J Hepatol (2009) 0.81
Antitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosa. Neoplasia (2007) 0.81
Cytokines regulate cysteine cathepsins during TLR responses. Cell Immunol (2010) 0.81
Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. Mol Cancer (2011) 0.81
Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes. Front Chem (2015) 0.80
Stress-resistant Translation of Cathepsin L mRNA in Breast Cancer Progression. J Biol Chem (2015) 0.80
Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model. Int J Cancer (2016) 0.80
Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther (2015) 0.80
Targeting the Nuclear Cathepsin L- CCAAT-displacement protein/cut homeobox Transcription Factor-Epithelial Mesenchymal Transition Pathway in Prostate and Breast Cancer Cells with Z-FY-CHO Inhibitor. Mol Cell Biol (2016) 0.79
Targeting the lysosome in cancer. Ann N Y Acad Sci (2015) 0.79
Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma. Oncol Lett (2015) 0.79
Effects of cathepsin K deficiency on intercellular junction proteins, luminal mucus layers, and extracellular matrix constituents in the mouse colon. Biol Chem (2012) 0.79
M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues. J Hepatol (2012) 0.79
Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage. Acta Pharmacol Sin (2015) 0.79
Cathepsin L targeting in cancer treatment. Pharmacol Ther (2015) 0.79
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget (2016) 0.78
Evaluating the diagnostic and prognostic value of circulating cathepsin S in gastric cancer. Oncotarget (2016) 0.78
Targeting Cathepsin B for Cancer Therapies. Horiz Cancer Res (2015) 0.78
MT2-MMP induces proteolysis and leads to EMT in carcinomas. Oncotarget (2016) 0.78
Autophagy-Regulated ROS from Xanthine Oxidase Acts as an Early Effector for Triggering Late Mitochondria-Dependent Apoptosis in Cathepsin S-Targeted Tumor Cells. PLoS One (2015) 0.78
Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94. Clin Exp Metastasis (2016) 0.78
MAGUKs, scaffolding proteins at cell junctions, are substrates of different proteases during apoptosis. Cell Death Dis (2011) 0.78
A bioavailable cathepsin S nitrile inhibitor abrogates tumor development. Mol Cancer (2016) 0.78
Monocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic risk. Sci Rep (2015) 0.78
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature (1985) 9.78
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 8.75
A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 8.48
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (1989) 7.30
Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer (2004) 6.73
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
Validation of tissue microarray technology in breast carcinoma. Lab Invest (2000) 5.50
Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer (2003) 4.78
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol (1997) 4.22
Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A (1998) 3.60
ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A (2005) 3.57
Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci (2001) 3.51
Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest (2000) 3.47
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Lysosomal cysteine proteases: facts and opportunities. EMBO J (2001) 3.06
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity (1999) 3.01
Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A (2002) 2.54
Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A (1999) 2.48
A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell (2004) 2.44
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J (2000) 2.09
Cysteine cathepsins in human cancer. Biol Chem (2004) 1.91
Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A (2003) 1.83
Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res (1997) 1.82
The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer (2000) 1.82
Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem (2005) 1.79
Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med (2002) 1.48
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am J Pathol (2001) 1.39
Apoptotic pathways: involvement of lysosomal proteases. Biol Chem (2002) 1.38
Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A (2002) 1.37
Multiple roles for cysteine cathepsins in cancer. Cell Cycle (2004) 1.36
Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem (2001) 1.34
Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J Biol Chem (2000) 1.24
Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. Biol Chem (2002) 1.09
Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul (2002) 1.08
Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Relat Cancer (2005) 1.02
Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab Invest (1998) 0.95
Tissue microarray (TMA) applications: implications for molecular medicine. Expert Rev Mol Med (2003) 0.89
Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr Opin Oncol (2005) 0.84
Release of cathepsin B precursors from human and murine tumours. Prog Clin Biol Res (1985) 0.83
Extracellular regulation of cancer invasion: the E-cadherin-catenin and other pathways. Biochem Soc Symp (1999) 0.82
Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest (2000) 0.81
International network of cancer genome projects. Nature (2010) 20.35
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 10.39
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 4.38
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev (2009) 4.21
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol (2004) 3.40
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev (2011) 3.04
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2002) 3.02
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther (2005) 2.85
Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg (2004) 2.84
Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J Biol Chem (2002) 2.76
Specialized roles for cysteine cathepsins in health and disease. J Clin Invest (2010) 2.69
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 2.64
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 2.56
Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol (2005) 2.56
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
The value of splenic preservation with distal pancreatectomy. Arch Surg (2002) 2.27
Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des (2007) 2.26
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res (2006) 2.20
Endogenous Myc maintains the tumor microenvironment. Genes Dev (2011) 2.16
Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol (2003) 2.12
Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle (2007) 2.10
Proteolytic networks in cancer. Trends Cell Biol (2011) 2.10
Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell (2013) 2.09
Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci (2007) 2.07
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2003) 2.07
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res (2011) 1.85
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer (2002) 1.85
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A (2003) 1.83
Adenocarcinoma of the duodenum: importance of accurate lymph node staging and similarity in outcome to gastric cancer. Ann Surg Oncol (2004) 1.82
The NK receptor KLRG1 is dispensable for virus-induced NK and CD8+ T-cell differentiation and function in vivo. Eur J Immunol (2010) 1.72
Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia (2008) 1.70
Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol (2003) 1.69
Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med (2005) 1.69
Direct observation and adherence to tuberculosis treatment in Chongqing, China: a descriptive study. Health Policy Plan (2008) 1.68
Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood (2011) 1.66
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg (2005) 1.64
Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A (2010) 1.60
Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut (2011) 1.58
Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS One (2008) 1.55
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. J Gastrointest Surg (2003) 1.49
CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest (2011) 1.49
Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg (2003) 1.45
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res (2005) 1.44
Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg (2010) 1.43
Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem (2008) 1.43
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene (2005) 1.43
Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol (2011) 1.41
Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci (2009) 1.38
Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. J Exp Med (2008) 1.38
Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc Natl Acad Sci U S A (2002) 1.37
Multiple roles for cysteine cathepsins in cancer. Cell Cycle (2004) 1.36
Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell (2010) 1.35
Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol (2004) 1.34
Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest (2003) 1.33
Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation (2007) 1.31
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer (2010) 1.31
Protonation, photobleaching, and photoactivation of yellow fluorescent protein (YFP 10C): a unifying mechanism. Biochemistry (2005) 1.30
Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg (2007) 1.30
Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett (2009) 1.30
Toward computer-based cleavage site prediction of cysteine endopeptidases. Biol Chem (2003) 1.27